bis[(3S,4S)-6-acetyl-4-amino-2,2-dimethyl-3,4-dihydrochromen-3-yl] sulfate;hydrate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: bis[(3S,4S)-6-acetyl-4-amino-2,2-dimethyl-3,4-dihydrochromen-3-yl] sulfate;hydrate
• 化学式: C26H34N2O9S
• 分子量: 550.6
• InChiKey: ZWELOGTXMBMMNP-JPIABUGISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.32
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  167
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• [EN] PRO-DRUG COMPOUNDS<br/>[FR] COMPOSÉS DE PROMÉDICAMENTS
  申请人：PROXIMAGEN LTD

  公开号：WO2014140510A1

  公开（公告）日：2014-09-18

  A compound according to formula (I) or a hydrate, solvate, or pharmaceutically acceptable salt thereof: wherein where the integers Q, R2, A, R1, Z1, Z2, and Z3 are as defined in claim 1.

  根据公式（I）或其水合物、溶剂合物或药用可接受盐，其中整数Q、R2、A、R1、Z1、Z2和Z3的定义如权利要求1中所述。
• [EN] TONABERSAT PRODRUGS<br/>[FR] PROMÉDICAMENTS DE TONABERSAT
  申请人：PROXIMAGEN LTD

  公开号：WO2015097463A1

  公开（公告）日：2015-07-02

  The invention relates to pharmaceutically active compounds having improved pharmacokinetic properties and being useful for the treatment or prevention of a range of conditions including migraine, epilepsy, non-epileptic seizures, brain injury (including stroke, intracranial haemorrhage and trauma induced) or cardiovascular diseases including myocardial infarction, coronary revascularization or angina. The compounds of the invention form a novel group of related prodrugs of formula (II), where Ar is a 3-chloro-4-fluorophenyl ring, a 3-chlorophenyl ring or a 4-fluorophenyl ring; and R is a hydrolysable group comprising an amino group or an acidic group.

  本发明涉及具有改善药代动力学特性的药物活性化合物，可用于治疗或预防多种疾病，包括偏头痛、癫痫、非癫痫性发作、脑损伤（包括中风、颅内出血和创伤引起的）或心血管疾病，包括心肌梗死、冠状动脉再血管化或心绞痛。本发明的化合物形成了一组新型相关的前药，其化学式为（II），其中Ar为3-氯-4-氟苯环、3-氯苯环或4-氟苯环；R为可水解基团，包括氨基或酸性基团。
• [EN] PRODRUG COMPOUNDS<br/>[FR] COMPOSÉS DE TYPE PROMÉDICAMENT
  申请人：PROXIMAGEN LTD

  公开号：WO2015097461A1

  公开（公告）日：2015-07-02

  A compound of formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, Wherein Q, R2, Ar, A and R1 are as defined in claim 1. The claimed compounds are gap junction blockers useful for the treatment or prevention of a range of conditions including migraine, epilepsy, non-epileptic seizures, brain injury (including stroke, intracranial haemorrhage and trauma induced), pain, neurodegenerative disease or cardiovascular disease including myocardial infarction, coronary revascularization or angina.

  公式（Ia）或（Ib）的化合物，或其药学上可接受的盐，其中Q、R2、Ar、A和R1如权利要求1所定义。所述化合物是缝隙连接阻滞剂，可用于治疗或预防一系列疾病，包括偏头痛、癫痫、非癫痫性抽搐、脑损伤（包括中风、颅内出血和创伤引起的）、疼痛、神经退行性疾病或心血管疾病，包括心肌梗死、冠状动脉重建术或心绞痛。
• PRO-DRUG COMPOUNDS
  申请人：PROXIMAGEN LIMITED

  公开号：US20160016929A1

  公开（公告）日：2016-01-21

  A compound according to formula (I) or a hydrate, solvate, or pharmaceutically acceptable salt thereof: wherein where the integers Q, R 2 , A, R 1 , Z 1 , Z 2 , and Z 3 are as defined in claim 1 .

  一种化合物，其化学式为（I），或其水合物、溶剂化物或药学上可接受的盐，其中整数Q、R2、A、R1、Z1、Z2和Z3的定义如权利要求1所述。
• TONABERSAT PRODRUGS
  申请人：Proximagen Limited

  公开号：EP3087063A1

  公开（公告）日：2016-11-02